Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
- DOI
- 10.1634/theoncologist.2017-0690
- Published
- 2018 Jun
- Container
- The oncologist
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1634/theoncologist.2017-0690,
title = {Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.},
author = {von Pawel J and Spigel DR and Ervin T and Losonczy G and Barlesi F and Juhász E and Anderson M and McCall B and Wakshull E and Hegde P and Ye W and Chen D and Chang I and Rhee I and Reck M},
year = {2018},
journal = {The oncologist},
doi = {10.1634/theoncologist.2017-0690},
url = {https://doi.org/10.1634/theoncologist.2017-0690}
}RIS
TY - JOUR TI - Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer. AU - von Pawel J AU - Spigel DR AU - Ervin T AU - Losonczy G AU - Barlesi F AU - Juhász E AU - Anderson M AU - McCall B AU - Wakshull E AU - Hegde P AU - Ye W AU - Chen D AU - Chang I AU - Rhee I AU - Reck M PY - 2018 JO - The oncologist DO - 10.1634/theoncologist.2017-0690 UR - https://doi.org/10.1634/theoncologist.2017-0690 ER -
APA
J, V. P., DR, S., T, E., G, L., F, B., E, J., M, A., B, M., E, W., P, H., W, Y., D, C., I, C., I, R., & M, R. (2018). Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.. The oncologist. https://doi.org/10.1634/theoncologist.2017-0690
Source records
- pubmed · retrieved 2026-09-27T13:35:55.145Z